1. Home
  2. CPAY vs UTHR Comparison

CPAY vs UTHR Comparison

Compare CPAY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corpay Inc.

CPAY

Corpay Inc.

HOLD

Current Price

$401.79

Market Cap

25.8B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$543.59

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPAY
UTHR
Founded
1986
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.8B
23.1B
IPO Year
2010
1999

Fundamental Metrics

Financial Performance
Metric
CPAY
UTHR
Price
$401.79
$543.59
Analyst Decision
Buy
Buy
Analyst Count
16
15
Target Price
$461.00
★ $656.93
AVG Volume (30 Days)
484.0K
★ 691.8K
Earning Date
11-04-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
7.59
★ 13.07
EPS
8.79
★ 13.07
Revenue
★ $4,528,403,000.00
$1,483,300,000.00
Revenue This Year
$17.49
$0.16
Revenue Next Year
$8.61
$13.34
P/E Ratio
$45.43
★ $40.79
Revenue Growth
★ 13.93
2.38
52 Week Low
$252.84
$409.15
52 Week High
$427.46
$609.35

Technical Indicators

Market Signals
Indicator
CPAY
UTHR
Relative Strength Index (RSI) 51.98 58.05
Support Level $401.52 $526.30
Resistance Level $407.52 $595.41
Average True Range (ATR) 8.88 21.36
MACD 0.52 0.83
Stochastic Oscillator 62.06 64.57

Price Performance

Historical Comparison
CPAY
UTHR

About CPAY Corpay Inc.

Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: